Cargando…

The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study

OBJECTIVE: We aimed to study the association of parity number with multimorbidity (MM) and polypharmacy among women in the Azar cohort population. PATIENTS & METHODS: This cross-sectional investigation was based on data from the Azar Cohort Study. Information regarding demographics, personal hab...

Descripción completa

Detalles Bibliográficos
Autores principales: Faramarzi, Elnaz, Somi, Mohammd Hossein, Tutunchi, Helda, Almaspour, Hanieh, Sanaie, Sarvin, Asemani, Sanaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236573/
https://www.ncbi.nlm.nih.gov/pubmed/37264361
http://dx.doi.org/10.1186/s12905-023-02434-9
_version_ 1785052966312476672
author Faramarzi, Elnaz
Somi, Mohammd Hossein
Tutunchi, Helda
Almaspour, Hanieh
Sanaie, Sarvin
Asemani, Sanaz
author_facet Faramarzi, Elnaz
Somi, Mohammd Hossein
Tutunchi, Helda
Almaspour, Hanieh
Sanaie, Sarvin
Asemani, Sanaz
author_sort Faramarzi, Elnaz
collection PubMed
description OBJECTIVE: We aimed to study the association of parity number with multimorbidity (MM) and polypharmacy among women in the Azar cohort population. PATIENTS & METHODS: This cross-sectional investigation was based on data from the Azar Cohort Study. Information regarding demographics, personal habits, physical activity level, medical and reproductive history, and anthropometric measurements of 8,290 females (35–70 years) were evaluated. Ordinal logistic and logistic regression analyses were conducted to assess for associations of parity number with multimorbidity (MM), polypharmacy, chronic disease, and abdominal obesity. RESULTS: More educated participants and people in the fifth quintile of the Wealth Score Index were less likely to have a higher parity number. With increasing parity numbers, the prevalence of MM, polypharmacy, hypertension, cardiovascular disease, fatty liver disease, stroke, rheumatoid diseases, chronic obstructive pulmonary disease, and cancers tended to rise. Moreover, we found that increasing parity numbers (especially when ≥ 5) enhanced the odds of abdominal obesity, waist-to-hip ratio ≥ 0.85, and waist-to-height ratio ≥ 0.5; these significant associations were more obvious in parity numbers ≥ 9 and WHtR ≥ 0.5. CONCLUSION: The parity number is associated with MM and polypharmacy in Iranian women enrolled in the Azar Cohort Study. Further studies exploring the pathways (biological, social, and environmental) underlying these relationships will provide clues for preventing morbidity and premature mortality among susceptible andhighly parous women.
format Online
Article
Text
id pubmed-10236573
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102365732023-06-03 The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study Faramarzi, Elnaz Somi, Mohammd Hossein Tutunchi, Helda Almaspour, Hanieh Sanaie, Sarvin Asemani, Sanaz BMC Womens Health Research OBJECTIVE: We aimed to study the association of parity number with multimorbidity (MM) and polypharmacy among women in the Azar cohort population. PATIENTS & METHODS: This cross-sectional investigation was based on data from the Azar Cohort Study. Information regarding demographics, personal habits, physical activity level, medical and reproductive history, and anthropometric measurements of 8,290 females (35–70 years) were evaluated. Ordinal logistic and logistic regression analyses were conducted to assess for associations of parity number with multimorbidity (MM), polypharmacy, chronic disease, and abdominal obesity. RESULTS: More educated participants and people in the fifth quintile of the Wealth Score Index were less likely to have a higher parity number. With increasing parity numbers, the prevalence of MM, polypharmacy, hypertension, cardiovascular disease, fatty liver disease, stroke, rheumatoid diseases, chronic obstructive pulmonary disease, and cancers tended to rise. Moreover, we found that increasing parity numbers (especially when ≥ 5) enhanced the odds of abdominal obesity, waist-to-hip ratio ≥ 0.85, and waist-to-height ratio ≥ 0.5; these significant associations were more obvious in parity numbers ≥ 9 and WHtR ≥ 0.5. CONCLUSION: The parity number is associated with MM and polypharmacy in Iranian women enrolled in the Azar Cohort Study. Further studies exploring the pathways (biological, social, and environmental) underlying these relationships will provide clues for preventing morbidity and premature mortality among susceptible andhighly parous women. BioMed Central 2023-06-02 /pmc/articles/PMC10236573/ /pubmed/37264361 http://dx.doi.org/10.1186/s12905-023-02434-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Faramarzi, Elnaz
Somi, Mohammd Hossein
Tutunchi, Helda
Almaspour, Hanieh
Sanaie, Sarvin
Asemani, Sanaz
The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title_full The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title_fullStr The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title_full_unstemmed The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title_short The association of parity number with multimorbidity and polypharmacy among Iranian women in the Azarcohort: a cross-sectional study
title_sort association of parity number with multimorbidity and polypharmacy among iranian women in the azarcohort: a cross-sectional study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236573/
https://www.ncbi.nlm.nih.gov/pubmed/37264361
http://dx.doi.org/10.1186/s12905-023-02434-9
work_keys_str_mv AT faramarzielnaz theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT somimohammdhossein theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT tutunchihelda theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT almaspourhanieh theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT sanaiesarvin theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT asemanisanaz theassociationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT faramarzielnaz associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT somimohammdhossein associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT tutunchihelda associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT almaspourhanieh associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT sanaiesarvin associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy
AT asemanisanaz associationofparitynumberwithmultimorbidityandpolypharmacyamongiranianwomenintheazarcohortacrosssectionalstudy